C

Concentra Group Holdings Parent Inc
NYSE:CON

Watchlist Manager
Concentra Group Holdings Parent Inc
NYSE:CON
Watchlist
Price: 20.89 USD -1.6% Market Closed
Market Cap: $2.7B

Concentra Group Holdings Parent Inc
Investor Relations

Concentra Group Holdings Parent Inc., often just referred to as Concentra, thrives by specializing in occupational health services within the United States. Imagine a partner that steps in whenever a company needs to ensure its workforce remains healthy and efficient. Concentra does precisely that by offering a comprehensive suite of medical services tailored for the workplace. This includes everything from urgent care, physical therapy, and workplace wellness programs to preventative screenings. These services aren't just about treating injuries after they occur but extending beyond to prevent them in the first place, thereby ensuring minimal downtime for businesses and maximizing employee productivity.

The organization generates revenue primarily from three business lines: workers' compensation care, physical examinations, and drug testing for employers. By aligning closely with businesses, Concentra essentially positions itself as an extension of a company’s human resources and health safety departments, forming contractual agreements to provide ongoing health management services. Concentra benefits financially by establishing these prolonged relationships with corporate clients, who depend on their medical services to maintain a productive, healthy workforce. This continuity affords Concentra stable revenue streams, while their clinics, strategically placed near concentrated business hubs, ensure that they remain accessible for their day-to-day operational engagements.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Feb 27, 2026
AI Summary
Q4 2025

Strong Quarter: Concentra finished Q4 and FY2025 with robust results, surpassing the high end of its revenue and adjusted EBITDA guidance.

Revenue Growth: Total revenue grew 15.9% year-over-year in Q4 to $539.1 million, and 13.9% for the full year to $2.2 billion.

Visit Volumes: Patient visits per day in Q4 rose 9% to over 51,000, with organic visit growth even after excluding acquisitions.

Margin Expansion: Adjusted EBITDA margin improved to 17.7% in Q4 and 20% for the year, despite one-time integration and public company costs.

Cash Generation: Free cash flow for the year was $197.8 million, with healthy 114% free cash flow conversion.

2026 Guidance: For FY2026, Concentra expects revenue of $2.25–$2.35 billion, adjusted EBITDA of $450–$470 million, and free cash flow of $200–$225 million.

De Novo & M&A: The company is planning a record 7–9 new center openings in 2026 and will continue small, accretive acquisitions.

Labor & Market Outlook: Labor costs are stable with wage inflation of 2–3%, and management is optimistic about employment trends in their core markets.

Key Financials
Revenue
$539.1 million
Revenue (Full Year)
$2.2 billion
Revenue (excluding Nova and Pivot, Q4)
$493.8 million
Revenue (excluding Nova and Pivot, Full Year)
$2 billion
Patient Visits Per Day (Q4)
over 51,000
Patient Visits Per Day (Full Year)
over 53,000
Revenue Per Visit (Q4)
$150
Adjusted EBITDA (Q4)
$95.3 million
Adjusted EBITDA (Full Year)
$431.9 million
Adjusted EBITDA Margin (Q4)
17.7%
Adjusted EBITDA Margin (Full Year)
20%
Adjusted Net Income (Q4)
$36.1 million
Adjusted Earnings Per Share (Q4)
$0.28
Adjusted Net Income (Full Year)
$176 million
Adjusted Earnings Per Share (Full Year)
$1.37
Operating Cash Flow (Q4)
$118.7 million
Operating Cash Flow (Full Year)
$279.4 million
Free Cash Flow (Q4)
$98.6 million
Free Cash Flow (Full Year)
$197.8 million
Free Cash Flow Conversion (Full Year)
114%
Cost of Services as % of Revenue (Q4)
73.9%
Cost of Services as % of Revenue (Full Year)
71.7%
General and Administrative Expenses as % of Revenue (Q4)
9.4%
General and Administrative Expenses as % of Revenue (Full Year)
9.4%
Capital Expenditures (Full Year)
$82.3 million
Total Debt Balance (Q4)
$1.57 billion
Cash Balance (Q4)
$79.9 million
Net Leverage Ratio (Q4)
3.4x
Dividend Per Share (Q1 2026)
$0.0625
Earnings Call Recording
Other Earnings Calls

Management

Mr. William Keith Newton
CEO & Director
No Bio Available
Mr. Matthew T. DiCanio M.B.A., MBA
President & CFO
No Bio Available
Ms. Su Zan Nelson CPA, CPA
Executive VP & Chief Accounting Officer
No Bio Available
Mr. John A. deLorimier
Executive VP and Chief Information & Technology Officer
No Bio Available
Mr. Giovanni Gallara
Executive VP & Chief Clinical Services Officer
No Bio Available
Mr. Timothy F. Ryan
Executive VP & Chief Legal Counsel
No Bio Available
Mr. Thomas A. Devasia
Executive VP and Chief Marketing & Innovation Officer
No Bio Available
Dr. John R. Anderson DO, FACOEM
Executive VP & Chief Medical Officer
No Bio Available
Mr. Michael A. Kosuth
Executive VP & COO of East
No Bio Available
Mr. Douglas R. McAndrew
Executive VP & COO of West
No Bio Available

Contacts

Address
PENNSYLVANIA
Mechanicsburg
C/O Select Medical Corporation, 4714 Gettysburg Rd., P.O. Box 2034
Contacts
+17179721100
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett